

図5. LCAT欠損症において報告されている変異

ヒト *lcat* 遺伝子領域は6個のエクソンから構成されており、全てのエクソンに変異が同定されている。#: 本邦において報告されている変異。




図6. LCAT欠損症患者血清への rLCAT 添加による患者 HDL の成熟化

魚眼病 4 症例、家族性 LCAT 欠損症 4 症例について患者血清に前脂肪細胞が産生した rLCAT を添加インキュベーション後、HDL の成熟を二次元電気泳動後の ApoAI の検出により行った。




図 7. フィブリンゲルの生着促進効果

(A) フィブリンゲルとマトリゲルを scaffold として LCAT 遺伝子導入マウス前脂肪細胞を B6 マウスに皮下移植し、血中へのヒト LCAT 蛋白の分泌を経時的に検出した。

(B) (A) の検出バンドを定量化した。フィブリンゲル移植群 (▲) はマトリゲル移植群 (●) と比較して同等の分泌が認められた。

(C) フィブリンゲル移植群 (■) ではフィブリンゲル無し (□) で移植した群とフィブリンゲルでは有意に TUNEL 陽性 (アポトーシス陽性) 細胞が少ないことが観察された。




図 8. PRP のアポトーシス抑制効果

(A) 2%PRP 存在下では他の条件に比べて前脂肪細胞のアポトーシスが抑制されていた。そのメカニズムとしてアポトーシス関連遺伝子の発現を検討したところ、PRP は DAPK1 遺伝子 (B) と BIM 遺伝子 (C) の発現を抑制することでアポトーシス抑制に働くことが考えられた。




図 9. LCAT-KO マウス移植モデルにおける hLCAT の分泌と薬効評価

免疫抑制剤の投与下、hLCAT 遺伝子導入マウス前脂肪細胞 (m-ccdPA) を LCAT-KO マウスに移植し、移植前 4 日前 (-4)、移植 3 日後 (3)、移植 7 日後 (7)、14 日後 (14) の血清を採取、血中への分泌 (A、IP-Western Blot)、血中での LCAT 活性 (B)、各リポ蛋白分画におけるコレステロールエステル比を測定した。

(A) IP-Western に用いた血清量は 14 日後の検体は 100 μ l、その他は 10 μ l である。HDL を hLCAT ポジティブコントロールとして使用した。

(B) ヒト ApoAI の存在下 (□)、非存在下 (■) で活性を測定し、ヒト ApoAI 存在下での活性増強を認めた図 9. LCAT-KO マウス移植モデルにおけるコレステロールエステル比の変化

(C) CM、VLDL、LDL、HDL の 4 分画について総コレステロールと遊離コレステロール濃度を定量し、コレステロールエステル比 (CE/TC) を算出した。検討した 2 個体についていずれも移植前 (□) に比較して、移植 7 日後 (■) の HDL 分画における CE/TC 比の上昇を認めた。




図 10. LCAT 欠損症の病態と関連したリポ蛋白異常の解析

(A) C313Y変異を有する姉妹症例において、腎不全の合併・非合併によるリポ蛋白プロファイルに相違を見出した。(B) C74Y変異を保持する患者において、脂質制限食治療により腎機能の改善と関連したリポ蛋白プロファイルの変化を認めた。矢印で示すリポ蛋白の減少が腎機能障害と関連している可能性が示唆された。

(C) 家族性LCAT欠損症 (FLD)、魚眼病 (FED) の症例におけるリポ蛋白プロファイルを健常人と比較したところ、それぞれに特徴的なリポ蛋白サイズの異常を認めた。TC: 総コレステロール、TG: トリグリセリド、FC: 遊離コレステロール、PL: リン脂質。(D) 健常人ではVLDL、LDL分画のピークが分画5と9に認められるが、魚眼病 (FED) では5のピークが不明瞭になり、8にピークが出現する。家族性LCAT欠損症 (FLD) では、FEDに認められた8のピークに加えて、5にピークが認められた。FLDにおける5のピークを持つリポ蛋白は、健常人のその脂質組成とは明らかに異なっていた。




図11. 前脂肪細胞移植技術による酵素補充療法の技術基盤

本研究ではそれまでの臨床脂肪移植技術、文献報告等から考えられた脂肪細胞移植技術の安全性（上段）に基づく新たな治療技術開発を実施した。横軸（中央）に脂肪組織摘出から移植、病態の改善までを図示し、本研究で評価した前脂肪細胞の本治療技術に関する特性を下段に記載した。

II. 研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Fukaya Y, Kuroda M, Aoyagi Y, Asada S, Kubota Y, Okamoto Y, Nakayama T, Saito Y, Satoh K, Bujo H.	Platelet-rich plasma inhibits the apoptosis of highly adipogenic homogeneous preadipocytes in an <i>in vitro</i> culture system.	Exp Mol Med.	In press		2012
Aoyagi Y, Kuroda M, Asada S, Tanaka S, Konno S, Tanio M, Aso M, Okamoto Y, Nakayama T, Saito Y, Bujo H.	Fibrin glue is a candidate scaffold for long-term therapeutic protein expression in spontaneously differentiated adipocytes <i>in vitro</i> .	Exp Cell Res.	318	8-15	2012
Kuroda M, Bujo H, Aso M, Saito Y.	Adipocytes as a vehicle for <i>ex vivo</i> gene therapy: Novel replacement therapy for diabetes and other metabolic diseases.	J Diabet Invest.	2	333-340	2011
Katayama A, Wada J, Usui-Kataoka H, Yamasaki H, Teshigawara S, Terami T, Inoue K, Kanzaki M, Murakami K, Nakatsuka A, Sugiyama H, Koide N, Bujo H, Makino H.	Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations.	NDT Plus.	4	299-302	2011
Asada S, Kuroda M, Aoyagi Y, Fukaya Y, Tanaka S, Konno S, Tanio M, Aso M, Satoh K, Okamoto Y, Nakayama T, Saito Y, Bujo H.	Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy.	Am J Physiol Cell Physiol.	301	C181-C185	2011
Aoyagi Y, Asada S, Kuroda M, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Aso M, Saito Y.	Fibrin glue increases the cell survival and the transduced gene product secretion of the ceiling culture-derived adipocytes transplanted in mice.	Exp Mol Med.	43	161-167	2011
Kuroda M, Aoyagi Y, Asada S, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Machida K, Matsumoto F, Satoh K, Aso M, Saito Y.	Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle in enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency.	The Open Gene Ther J.	4	1-10	2011
Asada S, Kuroda M, Aoyagi Y, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Aso M, Saito Y.	Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes <i>in vitro</i> .	Mol Genet Metab.	102	229-231	2011
Nagayama D, Endo K, Ohira M, Yamaguchi T, Ban N, Kawana H, Nagumo A, Saiki A, Oyama T, Miyashita Y, Shirai K	Effects of body weight reduction on cardio-ankle vascular index (CAVI)	Obes Res Clin Pract.	In press		2012

Suzuki J, Sakakibara R, Tomaru T, Tateno F, Kishi M, Ogawa E, Kurosu T, Shirai K.	Stroke and Cardio-ankle Vascular Stiffness Index.	J Stroke Cerebrovasc Dis.	In press		2012
Namekata T, Suzuki K, Ishizuka N, Nakata M, Shirai K	Association of Cardio-Ankle Vascular Index with Cardiovascular Disease Risk Factors and Coronary Heart Disease among Japanese Urban Workers and their Families.	J Clinic Experiment Cardiol	S1	003	2012
Shirai K.	Analysis of vascular function using the cardio-ankle vascular index (CAVI)	Hypertens Res.	34	684-685	2011
Namekata T, Suzuki K, Ishizuka N, Shirai K.	Establishing baseline criteria of cardio-ankle vascular index as a new indicator of arteriosclerosis: a cross-sectional study	BMC Cardiovasc Disord.	11	51	2011
Endo K, Saiki A, Ohira M, Miyashita Y, Shirai K.	Cardio-ankle vascular index may reflect endothelial function in type 2 diabetes.	Int J Clin Pract.	65	1200-1201	2011
Shirai K.	Analysis of vascular function using the cardio-ankle vascular index (CAVI).	Hypertens Res.	34	684-685	2011
Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, Miyashita Y, Saiki A, Takahashi M, Suzuki K, Takata M.	Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives.	J Atheroscler Thromb.	18	924-938	2011
Shirai K, Song M, Suzuki J, Kurosu T, Oyama T, Nagayama D, Miyashita Y, Yamamura S, Takahashi M.	Contradictory effects of β 1- and α 1- adrenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI)--CAVI independent of blood pressure.	J Atheroscler Thromb.	18	49-55	2011
Noike H, Nakamura K, Sugiyama Y, Iizuka T, Shimizu K, Takahashi M, Hirano K, Suzuki M, Mikamo H, Nakagami T, Shirai K.	Changes in cardio-ankle vascular index in smoking cessation.	J Atheroscler Thromb.	17	517-525	2010
Nagayama D, Saiki A, Endo K, Yamaguchi T, Ban N, Kawana H, Ohira M, Oyama T, Miyashita Y, Shirai K.	Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients.	Int J Clin Pract.	64	1796-1801	2010
Saiki A, Olsson M, Jernäs M, Gummeson A, McTernan PG, Andersson J, Jacobson P, Sjöholm K, Olsson B, Yamamura S, Walley A, Froguel P, Carlsson B, Sjöström L, Svensson PA, Carlsson LM.	Tenomodulin is highly expressed in adipose tissue, increased in obesity, and down-regulated during diet-induced weight loss.	J Clin Endocrinol Metab.	94	3987-3994	2009

Kubota Y, Kuroki T, Akita S, Koizumi T, Hasegawa M, Rikihisa N, Mitsukawa N, Satoh K.	Association between plate location and plate removal following facial fracture repair.	Plast Reconstr Aesthet Surg.	65	372-378	2012
Akita S, Kuroki T, Yoshimoto S, Rikihisa N, Satoh K.	Reconstruction of a fingertip with a thenar perforator island flap.	J Plast Surg Hand Surg.	45	294-299	2011
Yokoyama T, Tosa Y, Kadomatsu K, Sato K, Hosaka Y.	A novel approach for preventing the development of persistent vasospasms after microsurgery for the extremities: intermittent topical lidocaine application.	J Reconstr Microsurg.	26	79-85	2010
Koizumi T, Negishi M, Nakamura S, Oguro H, Satoh K, Ichinose M, Iwama A.	Depletion of Dnmt1-associated protein 1 triggers DNA damage and compromises the proliferative capacity of hematopoietic stem cells.	Int J Hematol.	91	611-619	2010
Mitsukawa N, Satoh K.	Maxillomandibular distraction osteogenesis for Marshall-Smith syndrome.	J Plast Reconstr Aesthet Surg.	63	e611-e614	2010
Yokote, K., Shimano H, Urashima M, Teramoto T.	Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis.	Expert Rev Cardiovasc Ther.	9	555-562	2011
Tsurutani Y, Fujimoto M, Takemoto M, Irisuna H, Koshizaka M, Ohnishi S, Ishikawa T, He P, Honjo S, Maezawa Y, Saito Y, Yokote, K.	The roles of transforming growth factor- β and Smad3 signaling in adipocyte differentiation and obesity.	Biochem Biophys Res Commun.	407	68-73	2011
Takeda Y, Nakaseko C, Tanaka H, Takeuchi M, Yui M, Saraya A, Miyagi S, Wang C, Tanaka S, Ohwada C, Sakaida E, Yamaguchi N, Yokote, K., Hennighausen L, Iwama A.	Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.	Br J Haematol.	153	589-598	2011
Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, Sugano S, Sato E, Nagao T, Yokote K, Tatsuno I, Prives C.	Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species.	Proc Natl Acad Sci USA	107	7461-7466	2010
Isose S, Misawa S, Sakurai K, Kanai K, Shibuya K, Sekiguchi Y, Nasu S, Noto Y, Fujimaki Y, Yokote K, Kuwabara S.	Mexiletine suppresses nodal persistent sodium currents in sensory axons of patients with neuropathic pain.	Clin Neurophysiol.	121	719-724	2010

Ogiwara Y, Mori S, Iwama M, Sawabe M, Takemoto M, Kanazawa N, Furuta K, Fukuda I, Kondo Y, Kimbara Y, Tamura Y, Chiba Y, Araki A, Yokote K, Maruyama N, Ito H.	Hypoglycemia due to ectopic secretion of insulin-like growth factor-I in a patient with an isolated sarcoidosis of the spleen.	Endocr J.	57	325-330	2010
Kimura K, Shimano H, Yokote K, Urashima M, Teramoto T.	Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study.	J Atheroscler Thromb.	17	601-609	2010
Shimoyama T, Hiraoka S, Takemoto M, Koshizaka M, Tokuyama H, Tokuyama T, Watanabe A, Fujimoto M, Kawamura H, Sato S, Tsurutani Y, Saito Y, Perbal B, Koseki H, Yokote K.	CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migration.	Arterioscler Thromb Vasc Biol.	30	675-682	2010
黒田正幸、武城英明	脂質異常症の遺伝子治療. 特集「脂質異常症—日常診療に必要な知識をまとめよう—」石橋俊（自治医科大学）企画.	カレントテラピー	30	264-265	2012
黒田正幸、武城英明	脂肪細胞による新規蛋白質補充療法—LCAT 欠損症遺伝子治療臨床研究—.	医学のあゆみ	233	1246-1247	2010

Ⅲ. 研究成果の刊行物・別冊

Platelet-rich plasma inhibits the apoptosis of highly adipogenic homogeneous preadipocytes in an *in vitro* culture system

Yoshitaka Fukaya¹, Masayuki Kuroda^{2,3,*}, Yasuyuki Aoyagi^{2,3}, Sakiyo Asada^{2,3}, Yoshitaka Kubota¹, Yoshitaka Okamoto², Toshinori Nakayama⁴, Yasushi Saito⁵, Kaneshige Satoh¹, and Hideaki Bujo³

¹Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan

²Center for Advanced Medicine, Chiba University Hospital, Chiba, Japan

³Department of Genome Research and Clinical Application, Graduate School of Medicine, Chiba University, Chiba, Japan

⁴Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan

⁵Chiba University, Chiba, Japan

*Corresponding author: Masayuki KURODA, Ph.D.

Current address: Center for Advanced Medicine, Chiba University Hospital

1-8-1, Inohana, Chuo-ku, Chiba, 260-0856, Japan.

Tel.: +81-43-222-7171, or +81-43-441-4121

Fax: +81-43-226-8130

E-mail: kurodam@faculty.chiba-u.jp

Running title: PRP prevents apoptosis of *in vitro* cultured adipocytes.

Abstract

Auto-transplantation of adipose tissue is commonly used for the treatment of tissue defects in plastic surgery. The survival of the transplanted adipose tissue is not always constant, and one of reasons is the accelerated apoptosis of the implanted preadipocytes. We have recently established highly homogeneous preadipocytes, named ccdPAs. The aim of the current study was to evaluate the regulation of the potency of platelet-rich plasma (PRP) on the apoptosis of ccdPAs *in vitro*. PRP stimulated the proliferation of the preadipocytes in a dose-dependent manner, and the stimulatory activity of 2% PRP was significantly higher than that of 2% FBS or 2% platelet-poor plasma (PPP). The presence of 2% PRP significantly inhibited serum starvation- or TNF- α /cycloheximide-induced apoptosis in comparison to 2% FBS or 2% PPP. DAPK1 and BIM mRNAs were reduced in the preadipocytes cultured with 2% PRP in comparison to those cultured in 2% FBS. The gene expression levels were significantly higher in cells cultured without serum in comparison to cells cultured with 2% FBS, and the levels in the cells with 2% PRP were reduced to 5-10% of those in the cells without serum. These results indicated that ccdPAs exhibit anti-apoptotic activities, in addition to increased proliferation, when cultured in 2% PRP in comparison to the same concentration of FBS, and that this was accompanied with reduced levels of DAPK1 and BIM mRNA expression in *in vitro* culture. PRP may improve the outcome of transplantation of adipose tissue by enhancing the anti-apoptotic activities of the implanted preadipocytes.

Key words: preadipocytes; platelet-rich plasma (PRP); apoptosis; transplantation; DAPK1; BIM

Introduction

Aspirated fat is a common source of autologous tissue transplantation for the correction of tissue defects in plastic and reconstructive surgery (Billings and May, 1989; Patrick, 2000; Patrick, 2001). Aspirated fat contains multipotential preadipocytes and progenitor cells, which have been utilized as a source of cell-based regenerative medicine (Stashower *et al.*, 1999; Zuk *et al.*, 2001; Gimble *et al.*, 2007; Yoshimura *et al.*, 2009; Bauer-Kreisel *et al.*, 2010; Sterodimas *et al.*, 2010). Although several different techniques of fat grafting have been developed, the outcomes of the transplantation vary widely. The most important factor required for successful grafting is to optimize the survival of the transplanted preadipocytes and other cells in the graft. In previous studies, we and others have shown that various cytokines are involved in the efficient cell survival of the implants (Kimura *et al.*, 2003; Yamaguchi *et al.*, 2005; Cho *et al.*, 2006; Torio-Padron *et al.*, 2007; Kuramochi *et al.*, 2008; Ning *et al.*, 2009).

Platelet rich plasma (PRP) (Eppley *et al.*, 2006; Foster *et al.*, 2009; Redler *et al.*, 2011) has been widely applied for practical medicine, such as aesthetic plastic surgery and the treatment of soft-tissue ulcers (Welsh, 2000; Man *et al.*, 2001; Margolis *et al.*, 2001; Bhanot and Alex, 2002; Martinez-Zapata *et al.*, 2009; Sclafani, 2009). Once activated, platelets secrete various bioactive cytokines, including platelet-derived growth factor (PDGF) and transforming growth factor beta 1 (TGF- β 1), which increase angiogenesis and cell proliferation relevant to soft tissue regeneration. PRP has been applied for fat grafting, and in fact, has been shown to improve the survival of implanted adipose tissue in patients (Abuzeni and Alexander, 2001; Sadati *et al.*, 2006; Cervelli *et al.*, 2009). Thus, the use of PRP has been broadened to the tissue-engineering field using adipose tissue-derived multi-potential cells (Anitua *et al.*, 2006; Muller *et al.*, 2009). PRP is also expected to function as an autologous fibrin-based scaffold for transplanted cells (Anitua *et al.*, 2006; Wu *et al.*, 2009; Kang *et al.*, 2011). In fact, recent our study showed that fibrin-based scaffold decreased the apoptotic cell death of murine ccdPAs in mice transplantation model (Aoyagi *et al.*, 2011).

We have recently identified proliferative preadipocytes, ceiling culture-derived proliferative adipocytes (ccdPAs), as homogeneous cells suitable for *ex vivo* gene therapy applications via autologous transplantation (Asada *et al.*, 2011; Kuroda *et al.*, 2011). The ccdPAs are characterized by their high proliferative capacity with spontaneous adipogenic potential in scaffold fibrin gel culture (Aoyagi *et al.*, 2012). The establishment of a highly homogenous preadipocyte line made it possible to perform examinations to identify the optimal scaffolds and cytokines that can be used to improve the survival of transplanted preadipocytes. We herein studied the effects of PRP, and an autologous cytokine cocktail, on the apoptotic properties of preadipocytes using the ccdPAs.

Results

PRP inhibits fibrin scaffold gel shrinkage and improves the viability of ccdPAs in 3-dimensional culture

We have recently established a 3-dimensional (3-D) culture system for ccdPAs using fibrin gel (FG) (Aoyagi *et al.*, 2012). Using the 3-D culture system, the effects of PRP on the gel shrinkage and cell viability were analyzed in comparison to FBS. The FG/ccdPAs were formed and maintained in culture medium containing 10% FBS for 16 hr. The culture medium was replaced with fresh medium containing 2% PRP, 2% FBS or 10% FBS, or with medium without serum, and cells were subsequently incubated for an additional 24 hr.

The resulting gel sizes varied among the cultures grown in each type of medium. The gels without serum or with 2% FBS showed a drastic volume reduction, while the volumes of the gels cultured with 10% FBS or 2% PRP were not obviously reduced (Fig. 1A). The culture supernatants were collected from each well and LDH activity was measured to evaluate the viability of cells. The LDH activity significantly decreased in the culture medium with 2% PRP in comparison to the medium with 2% or 10% FBS (Fig. 1B). TUNEL staining of the gel sections showed the number of apoptotic cells to significantly decrease in the medium with 2% PRP in comparison to the medium with 2% FBS ($1.5 \pm 1.1\%$ vs $9.8 \pm 1.9\%$, $p < 0.05$). These results suggested that 2% PRP inhibits the shrinkage of FG/ccdPAs gels, and improves the cell viability in comparison to the same concentration of FBS.

PRP has a high proliferation-inducing potential for ccdPAs in plate culture

In order to evaluate the function of PRP on cell survival in the gel, we next examined the effects of PRP on the proliferation of ccdPAs in comparison to FBS. The cells (2.5×10^5 cells) were seeded and incubated with DMEM/HAM containing 20% FBS in 10 cm dishes for 16 hr. The media was replaced with medium containing 2% PRP, 2% FBS, or 10% FBS, and the cells were then cultured for 3 days. The cell appearance was not apparently changed among the ccdPAs cultured for 3 days in plates with media containing 2% PRP, 2% FBS, or 10% FBS (Fig. 2A). To examine the cell proliferation, 2×10^3 cells of ccdPAs were seeded onto 96 well plates and incubated at 37°C for 24 hr. The media was replaced with medium with or without 2% PRP, 2% FBS, or 10% FBS (Day 0), and the cells were cultured for 3 days. The number of cells in each well was evaluated by measuring the DNA content. In contrast to the observation that the cell numbers on Day 3 were not significantly changed in comparison to those at Day 0 in the cultures incubated in medium containing 2% FBS, the cell numbers were significantly increased in cells cultured in the medium with 10% FBS or 2% PRP, and notably, the number of cells on Day 3 in the medium containing 2% PRP was significantly increased in comparison to the cells cultured with 10% FBS (Fig. 1B). The cell numbers in the media with various concentrations of PRP showed a dose-dependent increase up to 5% PRP; the number of cells present in the media with 0.5-1% PRP was almost equivalent to that of the cells cultured with 5-10% FBS (Fig. 2C). These results indicated that the proliferation-inducing potential of PRP for ccdPAs was higher in comparison to that of FBS.

PRP inhibits the apoptosis of ccdPAs

The high proliferation-inducing property of PRP for ccdPAs in culture prompted us to further analyze PRP for protective effects against apoptosis in ccdPAs, since PRP is rich in cytokines and proteinases involved not only in proliferation, but also in regulating apoptosis (Eppley *et al.*, 2004; Eppley *et al.*, 2006; Foster *et al.*, 2009; Redler *et al.*, 2011). The protection of the cells from death may contribute to their longer survival after transplantation, together with a high potential for proliferation. To investigate the possibility, the ccdPAs (1×10^6 cells) were seeded and incubated in a 10 cm dish with DMEM/HAM medium containing 20% FBS for 16 hr, and subsequently incubated with the medium with or without 2% FBS, 2% PRP, or 2% PPP. After incubation for 8 hr, the cells were collected and stained with Annexin V-FITC. The flow cytometric analysis showed that 5.5% of cells were identified as Annexin V positive in the medium without serum (Fig. 3A). The number of apoptotic cells was significantly decreased in the media with 2% FBS, 2% PRP, or 2% PPP in comparison to that in the cells cultured in serum-free medium. Among the various supplements, 2% PRP drastically reduced the number of apoptotic cells in comparison to 2% FBS or 2% PPP. ERK1/2 phosphorylation was examined to further analyze the protective effect of PRP against apoptosis, because the activation of the cascade is important for apoptosis via various intracellular signals including TNF- α (Cawthorn and Sethi, 2008; Mebratu and Tesfaigzi, 2009; Cagnol and Chambard, 2010). The cells were incubated with 2% PRP, FBS, or PPP for 2 hr, and apoptosis was induced by TNF- α and cycloheximide. Phosphorylation was detected following treatment with TNF- α and cycloheximide for 5 min in the cells cultured with 2% FBS. A densitometric analysis showed the amount of phosphorylated ERK2, and not phosphorylated ERK1, to significantly decrease in the medium with 2% PRP in comparison to the medium with 2% FBS (Fig. 3B). The caspase-3 activity induced by TNF- α and cycloheximide for 3 hr were also significantly decreased in ccdPAs in the medium with 2% PRP in comparison to the cells cultured with 2% FBS or 2% PPP (Fig. 3C). Thus, the apoptosis of ccdPAs was inhibited by culturing them in the medium with 2% PRP *in vitro*.

PRP almost completely inhibits the expression of the pro-apoptotic genes, DAPK1 and BIM, in ccdPAs after serum starvation

In order to identify the molecules involved in the anti-apoptotic effects of PRP on ccdPAs in culture, the expression profiles of representative apoptosis-related genes were examined using a PCR array profiler. The cells (2.5×10^5 cells) were seeded into 10 cm dishes and incubated in DMEM/HAM containing 20% FBS for 16 hr. The media was replaced with DMEM/HAM containing 2% PRP or FBS, the cells were incubated for 3 days, and the total RNA was isolated from the cultured cells to analyze the expression of apoptosis-related genes. Two independent experiments showed that, among the 84 genes examined, there were 8 genes with a more than 2-fold increase in expression, and 9 genes with a more than 2-fold decrease in expression in the cells cultured in the medium with 2% PRP compared with those cultured in the medium with 2% FBS (Table 1). We focused our interest on two genes, DAPK1 (reduced to 7.4% of the expression level observed with FBS) and BCL2L11 (also called BIM, reduced to 18.9% of the level observed with FBS), as representative genes with the obvious downregulation in the medium with 2% PRP (Fig. 4). DAPK1 and BIM have been shown to be one of master regulators of cell death (Gozuacik and Kimchi, 2006), and is essential for BAX-dependent cell death (Kim *et al.*, 2009; Ren *et al.*, 2010), respectively.

The role of DAPK1 and BIM genes in apoptosis of preadipocytes was investigated by examining the effect of serum starvation of cells incubated with PRP on the expressions of these genes. The ccdPAs (2.5×10^5 cells) were seeded into 10 cm dishes and incubated in DMEM/HAM containing 20% FBS for 16 hr. The medium was replaced by medium containing 10% FBS (control), 2% FBS, 2% PRP, or 2% PPP, the cells were cultured for 3 days and the expression of DAPK1 and BIM were analyzed. The DAPK1 mRNA level was increased 10.6-fold by serum starvation in comparison to the level in the cells cultured with 10% FBS, and the mRNA level was decreased to that of 10% FBS by the presence of 2% PRP. It is worth noting that, although the mRNA levels of DAPK1 in the cells cultured with 2% FBS and 2% PPP significantly decreased in comparison to those cultured without serum, the reductions were by 20.4% and 11.9%, respectively, which were less than that (93.6%) induced by culture in 2% PRP. The BIM mRNA levels were also drastically increased in the cells cultured in serum free medium in comparison to those cultured in the medium with 10% FBS (Fig. 2C). The mRNA levels were reduced to those observed in the cells cultured with 10% FBS by the addition of 2% PRP. Again, the potential of 2% PRP to inhibit the mRNA expression of the target gene (by 87.2%) was significantly higher than that of the 2% FBS (54.1%) or 2% PPP (72.2%). Thus, PRP almost completely inhibited the expression of apoptosis-related genes induced by serum starvation.

Discussion

PRP inhibited the volume reduction of the 3D gels embedded with ccdPAs, the homogeneous preadipocytes, in comparison to the same concentration of FBS, and this was accompanied by increased cell viability in the gel. These observations prompted us to analyze the effects of PRP on the apoptosis and proliferation of the ccdPAs. The results showed that 2% PRP had a higher inhibitory effect on the apoptotic cell death of ccdPAs than 2% FBS or 2% PPP (see Fig. 3). A comparison between 2% PRP and 2% FBS by a gene expression profile analysis revealed that PRP downregulated 11% of the 84 representative apoptosis-related genes and upregulated 10% of the 84 representative apoptosis-related genes (see Fig. 4 and Table 1). The most drastically reduced genes were DAPK1, the protein product of which plays important roles in a wide range of signal transduction pathways with diverse outcomes, such as apoptosis, autophagy and immune responses (Lin *et al.*, 2010), and BIM, encoding one of the BH3-only proteins, which is a critical regulator of apoptosis in many cell types (Ramesh *et al.*, 2009). The induction of these genes by apoptotic stimuli was almost completely prevented in the presence of PRP (see Fig. 5).

PRP, a concentrate of physiological cytokines, has been widely utilized as an injectable material in the clinic since the 1970s to enhance soft and hard tissue healing (Andia *et al.*, 2010; Lopez-Vidriero *et al.*, 2010; Redler *et al.*, 2011; Yu *et al.*, 2011), mainly by stimulating cell proliferation and angiogenesis in the injured tissues. PRP promotes the growth of various cells, including tissue-derived progenitor cells (Liu *et al.*, 2002; Lucarelli *et al.*, 2003; Doucet *et al.*, 2005; Frechette *et al.*, 2005; Vogel *et al.*, 2006; Kakudo *et al.*, 2008; Kurita *et al.*, 2008; Cervelli *et al.*, 2009; Chierigato *et al.*, 2011), and increases the revascularization of the transplanted tissues (Bir *et al.*, 2009). Based on these findings, the clinical applications of PRP have been broadened to recommend its use as an additive to tissue/cell transplantation therapies in plastic and reconstructive surgeries, and more recently in regenerative medicine. In fact, PRP has been shown to improve the fat graft survival (Abuzeni and Alexander, 2001; Sadati *et al.*, 2006; Cervelli *et al.*, 2009; Nakamura *et al.*, 2010; Pires Fraga *et al.*, 2010; Oh *et al.*, 2011) and bone and periodontal regenerations via cell transplantation (Tobita *et al.*, 2008; Chen *et al.*, 2010; Yamada *et al.*, 2010; Arvidson *et al.*, 2011).

In order to apply PRP for clinical transplantation therapy using preadipocytes cultured *in vitro*, it is necessary to elucidate the effects of PRP on cell survival in the grafts. However, the mechanisms by which PRP increases graft survival have not been well-characterized so far. The current study showed that PRP strongly induces the proliferation of ccdPAs, preadipocytes which were previously shown to be more adipogenic than ASCs (Asada *et al.*, 2011), compared with FBS at an equivalent concentration. Vogel *et al.* (Vogel *et al.*, 2006) described that, because the addition of 2% PRP did not result in sufficient thrombocyte-clot formation to maintain a clot in the medium, a higher concentration of PRP, 3%, was evaluated for the stimulation of the MSC proliferation. In this study, to evaluate the efficacy of lower concentrations of PRP, the PRP was activated by thrombin to release cytokines (Aiba-Kojima *et al.*, 2007) prior to the experiments. As a result, 2% PRP showed almost the same effects on proliferation as 10% PRP, indicating its usability as a substitute for FBS in the expansion of preadipocytes for clinical applications. Finally, 2% PRP showed anti-apoptotic activities on the preadipocytes, providing evidence that it can be used as an efficacious additive in the cell transplantation cocktail.

We observed that the expression of the DAPK1 and BIM genes was substantially upregulated by serum starvation in ccdPAs. However, the addition of PRP in the growth media effectively inhibited the apoptosis and downregulated the expression of these genes. TGF- β has been shown to induce the expression of DAPK1 and BIM, and to lead to subsequent apoptosis in other cell types (Jang *et al.*, 2002; Wildey *et al.*, 2003; Ramjaun *et al.*, 2007; Yu *et al.*, 2008). PRP may therefore inhibit the TGF- β -induced apoptosis cascade(s) during serum starvation in ccdPAs. Further analyses are needed to elucidate the mechanism(s) underlying the inhibitory potential of PRP on the expression levels of the representative apoptotic genes. The gene expression analysis also showed that PRP regulated the expression levels of genes involved in TNF signaling (TNFRSF10A, TNFRSF25, TNFSF10, TNFRSF9, and TRAF2), and of the Bcl protein superfamily, with its related proteins (HRK, BNIP1, and BAG4) (see Table 1). The changes in the expression of these genes may also improve the survival of ccdPAs by modulating the apoptotic stimuli, considering that TNF- α signaling plays an important role in the regulation of the adipose tissue mass (Warne, 2003).

In conclusion, PRP inhibitions cell apoptosis as well as or better than FBS, and also promotes the proliferation of the ccdPAs. The gene expression analyses identified that the DAPK1 and BIM genes were the most highly downregulated apoptosis-related genes by PRP treatment in the preadipocytes. The identified characteristics of PRP with regard to the preadipocytes have advantages including increases in the cell number and improved cell survival in the transplanted grafts. Together with our findings for the efficacies of fibrin scaffold in transplantation of ccdPAs (Aoyagi *et al.*, 2011), the use of PRP for cell preparation and implantation of fat tissues and/or propagated cells may provide the graft with stable long-term survival after auto-transplantation.

Methods

Cell culture

Subcutaneous adipose tissues were obtained from healthy donors after informed consent was obtained, with approval from the ethics committee of Chiba University School of Medicine, and all studies were performed according to the guidelines of the Declaration of Helsinki. The preparation of the ceiling culture-derived proliferative adipocytes (ccdPAs) was performed as described previously (Kuroda *et al.*, 2011). Dulbecco's modified Eagle's medium/F12-HAM (DMEM/HAM, Sigma-Aldrich, St. Louis, MO) supplemented with 20% fetal bovine serum (FBS, SAFC Biosciences, Lenexa, KS) and 40 μ g/ml gentamicin (GENTACIN, Schering-Plough Co., Kenilworth, NJ) was used as the culture media, unless otherwise noted in the text.

Preparation of PRP

Human PRP and PPP were prepared from healthy donors as follows; 52 ml of blood was obtained from the donors and mixed with 8 ml of Anticoagulant Citrate Dextrose Solution Formula A (ACD-A, TERUMO, Tokyo, Japan) solution, and transferred to 15 ml tubes. The tubes were centrifuged at 300 \times g for 15 min at 20°C. The plasma and the buffy coat below the plasma were collected and transferred to new tubes. Secondary centrifugation was performed at 2000 \times g for 15 min at 20°C. The clear supernatant (plasma) was decanted off until 6 ml was left and the middle portion of supernatant (plasma) was taken to be used as PPP. Finally, the remaining supernatant including the buffy coat was taken to be used as PRP. The platelet number of each product was automatically measured (XS 800i, sysmex Japan). The PRP utilized in this study contained 8.6 \times 10⁶ platelets/ μ l, which was approximately 7-fold concentrated from the original concentration in whole human plasma. Preparations of serum lysates containing platelet-released growth factors were essentially performed according to the method described by Aiba-Kojima *et al.* (2007). In brief, 2U/ml of thrombin (Astellas Pharma Inc. Tokyo, Japan) was added to PRP and PPP, and the samples were agitated for 1 hr at 37°C and then incubated overnight at 4°C. Platelet bodies and any remaining fibrin were eliminated by centrifugation (2000 \times g for 10 min), and the supernatants were obtained for the PRP and PPP. The serum samples were frozen at -20°C and thawed at 37°C before use. The growth medium was supplemented with 2 U/ml of heparin (Novo-Heparin, 5,000 units/5 ml for Injection,

Mochida Pharm. Co. Tokyo, Japan).

Culture on fibrin scaffolds

Bolheal (The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan) was used as a clinically available material to generate the fibrin gel. Fibrinogen and thrombin solutions were diluted with Ringer's Solution (Fuso Pharmaceutical Industries, Osaka, Japan) containing 0.5% human serum albumin (Mitsubishi Tanabe Pharma., Tokyo, Japan). The ccdPAs were suspended at 1×10^7 cells/ml by the diluted fibrinogen and thrombin solution. The final concentration of fibrinogen was 4 mg/ml and the thrombin solution was used at 1 U/ml. To form fibrin clots, 50 μ l of the cell-fibrinogen suspension was added to each cell culture insert (Falcon 3104; Becton Dickinson, Franklin Lakes, NJ), then shortly thereafter, 50 μ l of the cell-thrombin suspension was added into the insert, mixed by pipetting, and incubated at room temperature for 2 hr. The inserts with fibrin clots were put on 12 well culture plates, and culture media were added to the inserts and wells. The plates were incubated at 37°C for 12 hr in a 5% CO₂ incubator, and the media were replaced by fresh media containing FBS or PRP.

LDH assay

LDH released into the culture supernatant from the FG/ccdPA was measured using the CytoTox-One Homogeneous Membrane Integrity Assay kit (Promega, Madison, WI). A 100 μ l sample of each culture supernatant was collected and added into to a 96-well plate. An equal volume of CytoTox-One Reagent was added and incubated for 10 min. Fifty μ l of Stop Solution was added and the sample fluorescence was measured on a fluorescence microplate reader (SPECTRA max GEMINI XPS, Molecular Devices, Carlsbad, CA) using a wavelength of 560 nm/590 nm for excitation/emission. The original culture medium before the serum concentration was changed served as a pre-treatment control sample and the control value was subtracted from the value obtained after incubation with the medium containing different concentrations of serum.

Cell proliferation assay

The cell proliferation was examined using the CyQUANT^R Cell Proliferation Assay Kit (Life Technologies, Carlsbad, CA). Cells were seeded into 96 well plates at a density of 2×10^3 cells per well with DMEM/HAM/20%FBS. After 24 hrs, the culture medium was removed and changed to fresh DMEM/HAM without serum, or with FBS, PRP or PPP. After 3 days, the microplates were gently inverted and blotted onto paper towels to remove the medium from the wells. The microplates were then frozen and stored at -80°C and thawed at room temperature prior to analysis. CyQUANT GR dye/cell-lysis buffer was added to each well. Cells were incubated at room temperature for 5 minutes and the sample fluorescence was measured on a fluorescence microplate reader (SPECTRA max GEMINI XPS, Molecular Devices) using wavelength of 480 nm/520 nm for excitation/emission.

Induction of apoptosis, and the annexin V binding and caspase 3 activity assays

The cells were seeded into 10 cm dishes at a density of 1×10^6 cells per well with DMEM/HAM/20%FBS. After 24 hrs, the culture medium was removed and changed to fresh DMEM/HAM with 2% FBS, 2% PRP or 2%PPP. After 2 hrs, apoptosis was induced by the addition of 100 ng/ml TNF- α (Peprotech, Rocky Hill, NJ) and 100 μ g/ml cycloheximide (CHX, Sigma-Aldrich). After 3 hrs, the culture supernatant was collected, and the cells were detached by TrypZean treatment. The detached cells were suspended in the collected culture supernatant. Subsequently, the cells were stained with Annexin V-FITC using a TaliTM Apoptosis kit (Life Technologies). Stained cells were analyzed by a TaliTM Image Based Cytometer (Life technologies). Cell lysates at the concentration of 1×10^4 cells/ μ l were prepared from the cells treated to induce apoptosis, and the caspase 3 activity levels were measured by a caspase-3/PPP32 Fluorometric Assay Kit (Biovision, Mountain View, CA). To examine the phosphorylation status of ERK1/2, the cells were scraped off at each time point in PBS and washed. The cells were pelleted and lysed by RIPA buffer (Wako Pure Chemical Industries, Ltd. Osaka, Japan), and the protein concentration was determined by Quant-iT Protein Assay Kit (Life technologies), and 5 μ g of protein were analyzed by Western blotting using anti-ERK1 and anti-ERK1/2 (pT202/pY204) as primary antibodies (BD Biosciences, Franklin Lakes, NJ). Mouse TrueBlot ULTRA HRP-conjugated Anti-Mouse IgG (eBioscience, Inc. San Diego, CA) was used as a secondary antibody, and the signals were detected by SuperSignal[®] West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific Inc.) with LAS1000 apparatus (FUJI film, Tokyo, Japan). ERK signals were normalized using Actin signals detected by Anti-Actin monoclonal antibody (clone AC-40, Sigma-Aldrich).

Gene expression analysis

Cells (2.5×10^5 cells) were seeded into 10 cm dish with DMEM/HAM/20% FBS and cultured for 16 hr. The culture medium was changed to fresh DMEM/HAM supplemented with 2% FBS or 2% PRP, and the cells were further incubated for 72 hrs. The total RNA from cultured cells was extracted using a RT² RNA Isolation Kit (SA Bioscience, Frederick, MD). Complementary DNA was generated from 1 μ g of total RNA using the RT² First Strand Kit. An Apoptosis Reverse Transcriptase RT² profiler PCR array and RT² Real-Time SYBR Green/ROX PCR Mix (SA Bioscience, Frederick, MD) were used to identify the genes affected by PRP according to manufacturer's instruction. The data were analyzed by web-based data analysis software provided by the manufacturer. The probe and primer sets used to quantify the mRNA for the DAPK1 and BIM genes were purchased from Applied Biosystems (Life Technologies). The quantification of given genes was expressed as the relative mRNA level compared with a control after normalization to 18S RNA. All the real-time PCR were performed using an ABI 7500 real-time PCR apparatus.

Statistical analysis

The data are presented as the means \pm S.D. Statistical comparisons were made by Student's *t*-test or an ANOVA followed by the post-hoc Tukey test using the SPSS software program. In all cases, P values < 0.05 were considered to be significant.

Acknowledgements

We thank Dr. Fumiaki Matsumoto, Mr. Shunichi Konno, Dr. Shigeaki Tanaka, and Mr. Masayuki Aso for helpful and valuable suggestions about our research. This study was supported by Health and Labour Sciences Research Grants for Translational Research, Japan (H. B.), and in part by the Global COE Program (Global Center for Education and Research in Immune System Regulation and Treatment), MEXT, Japan (Y.O., Y.N., and H.B.).

Figure legends

Figure 1. The effects of platelet-rich plasma (PRP) on the 3-dimensional culture of ccdPAs.

100 μ l of fibrin gels containing 1×10^7 cells/ml of ccdPAs (FG/ccdPAs) were formed in cell culture insert and incubated in DMEM/HAM with 10% FBS for 16 hrs. The medium was replaced by DMEM/HAM in the presence or absence of different concentrations of FBS or PRP. (A) Photographs of FG/ccdPAs in the inserts were taken after 24 hr of culture. (B) The culture supernatant was collected from each well and the LDH activities expressed by the fluorescence of resorufin generated by coupled enzymatic reaction were examined. * $p < 0.05$.

Figure 2. Platelet-rich plasma (PRP) promotes the proliferation of ccdPAs.

(A) Photographs of ccdPAs were taken after 3 days in culture containing DMEM/F12-HAM in the absence of serum (a) or the presence of 2% (b) or 10% (c) FBS or 2% (d) PRP. The scale bar indicates 200 μ m. (B) Cells were seeded into 96 well plates and incubated in DMEM/F12-HAM containing 20% FBS for 24 hr. The culture medium was then replaced with DMEM/F12-HAM in the absence of serum (control) or presence of 2% FBS or 10% FBS or 2% PRP. After 3 days in CO₂ incubator, the cell number in each well was examined by DNA content in comparison to those on day 0 (open bar). The values for the serum (-), 10% FBS, and 2% PRP groups were significantly different compared with those on Day 0 ($p < 0.05$). * $p < 0.05$. (C) The cell numbers were examined in wells cultured in DMEM/F12-HAM containing various concentrations of PRP (circle), FBS (triangle), and PPP (square) after 3 days of culture similarly as Fig. 2B. The growth stimulatory effect was not significantly different between 10% and 20% FBS and PPP (data not shown).

Figure 3. PRP decreased the apoptotic cell death and caspase 3 activity induced by TNF- α and cycloheximide in ccdPAs.

(A) ccdPAs were seeded and incubated for 16 hr with medium containing 20% FBS, and the medium was then replaced with fresh medium without serum (Serum (-)) or with media containing 2% PRP, FBS, or PPP, and the cells were subsequently incubated at 37°C for 8 hr. The cells were then collected, stained by Annexin V-FITC and propidium iodide (PI), and analyzed using a Tali™ Image Based Cytometer (Life technologies). FITC-positive/PI-negative cells were considered to be apoptotic cells. * $p < 0.05$. (B) After incubation for 16 hr with medium containing 20% FBS, ccdPAs were pretreated for 2 hr with the medium containing 2% PRP or FBS. The cells were treated with TNF- α and cycloheximide for 5, 30, 60, and 120 min in the medium with 2% FBS (closed bar) or 2% PRP (open bar). Cell lysates were prepared at each time point as well as pretreatment (pre) and then were subjected to an immunoblot analysis of phosphorylated or unphosphorylated form of ERK1/2, and Actin. Results of densitometric analysis of phosphorylated form of ERK2 (pERK2) is shown below. After normalization of signals of pERK2 by Actin, each value of pERK2 was expressed as the fold increase of that at 5 min with 2% FBS. * $p < 0.05$. (C) After pretreatment for 2 hr with the medium containing 2% PRP, FBS, or PPP, the cells were incubated for 3 hr in the absence (open bars) or presence (closed bars) of TNF- α and cycloheximide, which induce apoptotic cell death. The caspase-3 activity in the lysates of collected cells were measured. * $p < 0.05$.

Figure 4. The results of the analysis of the expression of apoptosis-related genes affected by PRP.

(A) Total RNA was extracted from the cells cultured in the presence of 2% FBS or 2% PRP for 72 hr. The total RNA was subjected to cDNA synthesis and subsequent quantification of the mRNA expression for various apoptosis-related genes. The fold-changes in the quantified mRNA amounts compared to the average value of house-keeping genes were plotted for each gene (x-axis; cultured in 2% FBS, y-axis; cultured in 2% PRP).

Figure 5. Serum starvation induced the expression of the DAPK1 and BIM genes, which was prevented by cultured with 2%PRP.

The ccdPAs were seeded and incubated for 16 hr in DMEM/HAM containing 20% FBS, and the culture medium was then replaced with medium without serum (Serum(-)), or with 2% or 10% FBS, 2% PRP, or 2% PPP, followed by incubation for an additional 72 hr. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) was performed to evaluate the mRNA expression levels of DAPK1 (A) and BIM (B). The quantification of the given genes was expressed as relative mRNA level compared with a control after normalization to 18S RNA. * $p < 0.05$.

Table 1. Apoptosis-related genes affected by PRP

Unigene	Refseq	Symbol	Description	Fold Change
Downregulated				
Hs.380277	NM_004938	DAPK1	Death-associated protein kinase 1	13.5803 ↓
Hs.469658	NM_006538	BCL2L11	BCL2-like 11 (apoptosis facilitator)	5.2596 ↓
Hs.5353	NM_001230	CASP10	Caspase 10, apoptosis-related cysteine peptidase	4.0726 ↓
Hs.591834	NM_003844	TNFRSF10A	Tumor necrosis factor receptor superfamily, member 10a	3.967 ↓
Hs.513667	NM_003946	NOL3	Nucleolar protein 3 (apoptosis repressor with CARD domain)	2.8887 ↓
Hs.501497	NM_001252	CD70	CD70 molecule	2.8129 ↓
Hs.87247	NM_003806	HRK	Harakiri, BCL2 interacting protein (contains only BH3 domain)	2.5816 ↓
Hs.710305	NM_004536	NAIP	NLR family, apoptosis inhibitory protein	2.3876 ↓
Hs.643120	NM_000875	IGF1R	Insulin-like growth factor 1 receptor	2.1732 ↓
Upregulated				
Hs.127799	NM_001165	BIRC3	Baculoviral IAP repeat-containing 3	10.851 ↑
Hs.462529	NM_003790	TNFRSF25	Tumor necrosis factor receptor superfamily, member 25	4.0981 ↑
Hs.478275	NM_003810	TNFSF10	Tumor necrosis factor (ligand) superfamily, member 10	4.0907 ↑
Hs.654459	NM_001561	TNFRSF9	Tumor necrosis factor receptor superfamily, member 9	2.9875 ↑
Hs.522506	NM_021138	TRAF2	TNF receptor-associated factor 2	2.8331 ↑
Hs.9216	NM_001227	CASP7	Caspase 7, apoptosis-related cysteine peptidase	2.2033 ↑
Hs.145726	NM_001205	BNIP1	BCL2/adenovirus E1B 19kDa interacting protein 1	2.0258 ↑
Hs.194726	NM_004874	BAG4	BCL2-associated athanogene 4	2.0241 ↑

Genes identified as having a change in expression > 2-fold induced by the addition of PRP in comparison to 2% FBS are shown.

References

- Abuzeni PZ, Alexander RW. Enhancement of autologous fat transplantation with platelet rich plasma. *Am J Cosmet Surg* 2001;18:59-70
- Aiba-Kojima E, Tsuno NH, Inoue K, Matsumoto D, Shigeura T, Sato T, Suga H, Kato H, Nagase T, Gonda K, Koshima I, Takahashi K, Yoshimura K. Characterization of wound drainage fluids as a source of soluble factors associated with wound healing: comparison with platelet-rich plasma and potential use in cell culture. *Wound Repair Regen* 2007;15:511-20
- Andia I, Sanchez M, Maffulli N. Tendon healing and platelet-rich plasma therapies. *Expert Opin Biol Ther* 2010;10:1415-26
- Anitua E, Sanchez M, Nurden AT, Nurden P, Orive G, Andia I. New insights into and novel applications for platelet-rich fibrin therapies. *Trends Biotechnol* 2006;24:227-34
- Aoyagi Y, Kuroda M, Asada S, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Aso M, Saito Y. Fibrin glue increases the cell survival and the transduced gene product secretion of the ceiling culture-derived adipocytes transplanted in mice. *Exp Mol Med* 2011;43:161-7
- Aoyagi Y, Kuroda M, Asada S, Tanaka S, Konno S, Tanio M, Aso M, Okamoto Y, Nakayama T, Saito Y, Bujo H. Fibrin glue is a candidate scaffold for long-term therapeutic protein expression in spontaneously differentiated adipocytes *in vitro*. *Exp Cell Res* 2012;318:8-15
- Arvidson K, Abdallah BM, Applegate LA, Baldini N, Cenni E, Gomez-Barrena E, Granchi D, Kassem M, Kontinen YT, Mustafa K, Pioletti DP, Sillat T, Finne-Wstrand A. Bone regeneration and stem cells. *J Cell Mol Med* 2011;15:718-46
- Asada S, Kuroda M, Aoyagi Y, Fukaya Y, Tanaka S, Konno S, Tanio M, Aso M, Satoh K, Okamoto Y, Nakayama T, Saito Y, Bujo H. Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy. *Am J Physiol Cell Physiol* 2011;301:C181-5
- Bauer-Kreisel P, Goepferich A, Blunk T. Cell-delivery therapeutics for adipose tissue regeneration. *Adv Drug Deliv Rev* 2010;62:798-813
- Bhanot S, Alex JC. Current applications of platelet gels in facial plastic surgery. *Facial Plast Surg* 2002;18:27-33
- Billings E, Jr., May JW, Jr. Historical review and present status of free fat graft autotransplantation in plastic and reconstructive surgery. *Plast Reconstr Surg* 1989;83:368-81
- Bir SC, Esaki J, Marui A, Yamahara K, Tsubota H, Ikeda T, Sakata R. Angiogenic properties of sustained release platelet-rich plasma: characterization *in-vitro* and in the ischemic hind limb of the mouse. *J Vasc Surg* 2009;50:870-9 e2
- Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. *FEBS J* 2010;277:2-21
- Cawthorn WP, Sethi JK. TNF- α and adipocyte biology. *FEBS Lett* 2008;582:117-31
- Cervelli V, Gentile P, Scioli MG, Grimaldi M, Casciani CU, Spagnoli LG, Orlandi A. Application of platelet-rich plasma in plastic surgery: clinical and *in vitro* evaluation. *Tissue Eng Part C Methods* 2009;15:625-34
- Chen FM, Zhang J, Zhang M, An Y, Chen F, Wu ZF. A review on endogenous regenerative technology in periodontal regenerative medicine. *Biomaterials* 2010;31:7892-927
- Chieragato K, Castegnaro S, Madeo D, Astori G, Pegoraro M, Rodeghiero F. Epidermal growth factor, basic fibroblast growth factor and platelet-derived growth factor-bb can substitute for fetal bovine serum and compete with human platelet-rich plasma in the *ex vivo* expansion of mesenchymal stromal cells derived from adipose tissue. *Cytotherapy* 2011;13:933-43
- Cho SW, Kim I, Kim SH, Rhie JW, Choi CY, Kim BS. Enhancement of adipose tissue formation by implantation of adipogenic-differentiated preadipocytes. *Biochem Biophys Res Commun* 2006;345:588-94
- Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. *J Cell Physiol* 2005;205:228-36
- Eppley BL, Pietrzak WS, Blanton M. Platelet-rich plasma: a review of biology and applications in plastic surgery. *Plast Reconstr Surg* 2006;118:147e-59e
- Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. *Plast Reconstr Surg* 2004;114:1502-8
- Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. *Am J Sports Med* 2009;37:2259-72
- Frechette JP, Martineau I, Gagnon G. Platelet-rich plasmas: growth factor content and roles in wound healing. *J Dent Res* 2005;84:434-9
- Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. *Circ Res* 2007;100:1249-60
- Gozuacik D, Kimchi A. DAPK protein family and cancer. *Autophagy* 2006;2:74-9
- Jang CW, Chen CH, Chen CC, Chen JY, Su YH, Chen RH. TGF- β induces apoptosis through Smad-mediated expression of DAP-kinase. *Nat Cell Biol* 2002;4:51-8
- Kakudo N, Minakata T, Mitsui T, Kushida S, Notodihardjo FZ, Kusumoto K. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. *Plast Reconstr Surg* 2008;122:1352-60
- Kang YH, Jeon SH, Park JY, Chung JH, Choung YH, Kim ES, Choung PH. Platelet-rich fibrin is a Bioscaffold and reservoir of growth factors for tissue regeneration. *Tissue Eng Part A* 2011;17:349-59
- Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. *Mol Cell* 2009;36:487-99
- Kimura Y, Ozeki M, Inamoto T, Tabata Y. Adipose tissue engineering based on human preadipocytes combined with gelatin microspheres containing basic fibroblast growth factor. *Biomaterials* 2003;24:2513-21
- Kuramochi D, Unoki H, Bujo H, Kubota Y, Jiang M, Rikihisa N, Udagawa A, Yoshimoto S, Ichinose M, Saito Y. Matrix metalloproteinase 2 improves the transplanted adipocyte survival in mice. *Eur J Clin Invest* 2008;38:752-9
- Kurita M, Aiba-Kojima E, Shigeura T, Matsumoto D, Suga H, Inoue K, Eto H, Kato H, Aoi N, Yoshimura K. Differential effects of three preparations of human serum on expansion of various types of human cells. *Plast Reconstr Surg* 2008;122:438-48
- Kuroda M, Aoyagi Y, Asada S, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Machida K, Matsumoto F, Satoh K, Aso M, Saito Y. Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin: cholesterol acyltransferase deficiency. *Open Gene Ther J* 2011;4:1-10
- Lin Y, Hupp TR, Stevens C. Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. *FEBS J* 2010;277:48-57
- Liu Y, Kalen A, Risto O, Wahlstrom O. Fibroblast proliferation due to exposure to a platelet concentrate *in vitro* is pH dependent. *Wound Repair Regen* 2002;10:336-40
- Lopez-Vidriero E, Goulding KA, Simon DA, Sanchez M, Johnson DH. The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment. *Arthroscopy* 2010;26:269-78
- Lucarelli E, Beccheroni A, Donati D, Sangiorgi L, Cenacchi A, Del Vento AM, Meotti C, Bertoja AZ, Giardino R, Fornasari PM, Mercuri M, Picci P. Platelet-derived growth factors enhance proliferation of human stromal stem cells. *Biomaterials* 2003;24:3095-100
- Man D, Plosker H, Winland-Brown JE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin

glue) in cosmetic surgery. *Plast Reconstr Surg* 2001;107:229-37; discussion 238-9

Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. *Diabetes Care* 2001;24:483-8

Martinez-Zapata MJ, Marti-Carvajal A, Sola I, Bolibar I, Angel Exposito J, Rodriguez L, Garcia J. Efficacy and safety of the use of autologous plasma rich in platelets for tissue regeneration: a systematic review. *Transfusion* 2009;49:44-56

Mebratu Y, Tesfaiqi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? *Cell Cycle* 2009;8:1168-75

Muller AM, Davenport M, Verrier S, Droeser R, Alini M, Bocelli-Tyndall C, Schaefer DJ, Martin I, Scherberich A. Platelet lysate as a serum substitute for 2D static and 3D perfusion culture of stromal vascular fraction cells from human adipose tissue. *Tissue Eng Part A* 2009;15:869-75

Nakamura S, Ishihara M, Takikawa M, Murakami K, Kishimoto S, Yanagibayashi S, Kubo S, Yamamoto N, Kiyosawa T. Platelet-rich plasma (PRP) promotes survival of fat-grafts in rats. *Ann Plast Surg* 2010;65:101-6

Ning H, Liu G, Lin G, Yang R, Lue TF, Lin CS. Fibroblast growth factor 2 promotes endothelial differentiation of adipose tissue-derived stem cells. *J Sex Med* 2009;6:967-79

Oh DS, Cheon YW, Jeon YR, Lew DH. Activated platelet-rich plasma improves fat graft survival in nude mice: a pilot study. *Dermatol Surg* 2011;37:619-25

Patrick CW, Jr. Adipose tissue engineering: the future of breast and soft tissue reconstruction following tumor resection. *Semin Surg Oncol* 2000;19:302-11

Patrick CW, Jr. Tissue engineering strategies for adipose tissue repair. *Anat Rec* 2001;263:361-6

Pires Fraga MF, Nishio RT, Ishikawa RS, Perin LF, Helene A, Jr., Malheiros CA. Increased survival of free fat grafts with platelet-rich plasma in rabbits. *J Plast Reconstr Aesthet Surg* 2010;63:e818-22

Ramesh S, Wildey GM, Howe PH. Transforming growth factor β (TGF β)-induced apoptosis: the rise & fall of Bim. *Cell Cycle* 2009;8:11-7

Ramjaun AR, Tomlinson S, Eddaoudi A, Downward J. Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis. *Oncogene* 2007;26:970-81

Redler LH, Thompson SA, Hsu SH, Ahmad CS, Levine WN. Platelet-rich plasma therapy: a systematic literature review and evidence for clinical use. *Phys Sportsmed* 2011;39:42-51

Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. *Science* 2010;330:1390-3

Sadati KS, Corrado AC, Alexander RW. Platelet-rich plasma (PRP) utilized to promote greater graft volume retention in autologous fat grafting. *Am J Cosmet Surg* 2006;23:203-211

Sclafani AP. Applications of platelet-rich fibrin matrix in facial plastic surgery. *Facial Plast Surg* 2009;25:270-6

Stashower M, Smith K, Williams J, Skelton H. Stromal progenitor cells present within liposuction and reduction abdominoplasty fat for autologous transfer to aged skin. *Dermatol Surg* 1999;25:945-9

Sterodimas A, de Faria J, Nicaretta B, Pitanguy I. Tissue engineering with adipose-derived stem cells (ADSCs): current and future applications. *J Plast Reconstr Aesthet Surg* 2010;63:1886-92

Tobita M, Uysal AC, Ogawa R, Hyakusoku H, Mizuno H. Periodontal tissue regeneration with adipose-derived stem cells. *Tissue Eng Part A* 2008;14:945-53

Torio-Padron N, Borges J, Momeni A, Mueller MC, Tegtmeier FT, Stark GB. Implantation of VEGF transfected preadipocytes improves vascularization of fibrin implants on the cylinder chorioallantoic membrane (CAM) model. *Minim Invasive Ther Allied Technol* 2007;16:155-62

Vogel JP, Szalay K, Geiger F, Kramer M, Richter W, Kasten P. Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics. *Platelets* 2006;17:462-9

Warne JP. Tumour necrosis factor α : a key regulator of adipose tissue mass. *J Endocrinol* 2003;177:351-5

Welsh WJ. Autologous platelet gel: clinical function and usage in plastic surgery. *Cosmet Dermatol* 2000;13:13-18

Wildey GM, Patil S, Howe PH. Smad3 potentiates transforming growth factor β (TGF β)-induced apoptosis and expression of the BH3-only protein Bim in WEHI 231 B lymphocytes. *J Biol Chem* 2003;278:18069-77

Wu W, Zhang J, Dong Q, Liu Y, Mao T, Chen F. Platelet-rich plasma - A promising cell carrier for micro-invasive articular cartilage repair. *Med Hypotheses* 2009;72:455-7

Yamada Y, Nakamura S, Ito K, Sugito T, Yoshimi R, Nagasaka T, Ueda M. A feasibility of useful cell-based therapy by bone regeneration with deciduous tooth stem cells, dental pulp stem cells, or bone-marrow-derived mesenchymal stem cells for clinical study using tissue engineering technology. *Tissue Eng Part A* 2010;16:1891-900

Yamaguchi M, Matsumoto F, Bujo H, Shibasaki M, Takahashi K, Yoshimoto S, Ichinose M, Saito Y. Revascularization determines volume retention and gene expression by fat grafts in mice. *Exp Biol Med (Maywood)* 2005;230:742-8

Yoshimura K, Suga H, Eto H. Adipose-derived stem/progenitor cells: roles in adipose tissue remodeling and potential use for soft tissue augmentation. *Regen Med* 2009;4:265-73

Yu J, Zhang L, Chen A, Xiang G, Wang Y, Wu J, Mitchelson K, Cheng J, Zhou Y. Identification of the gene transcription and apoptosis mediated by TGF- β -Smad2/3-Smad4 signaling. *J Cell Physiol* 2008;215:422-33

Yu W, Wang J, Yin J. Platelet-rich plasma: a promising product for treatment of peripheral nerve regeneration after nerve injury. *Int J Neurosci* 2011;121:176-80

Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 2001;7:211-28

Figure 1. Fukaya *et al.*




Figure 2. Fukaya *et al.*

